Home・Aandelen Lijst・AnaptysBio Inc

AnaptysBio Inc

Gesloten

SectorGezondheidszorg

56.23 3.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

54.52

Max

57.16

Belangrijke statistieken
By Trading Economics
Inkomsten	-102M -53M
Verkoop	-83M 26M
EPS	-1.843
Winstmarge	-206.934
Werknemers	104
EBITDA	-99M -31M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+42.5% upside

Dividenden
By Acuity
Volgende Winsten	11 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-388M 1.6B
Vorige openingsprijs	53.09
Vorige sluitingsprijs	56.23

Nieuwssentiment

By Acuity

50%

151 / 340 Rangschikking in Healthcare

AnaptysBio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 19:26 UTC

AnaptysBio Inc. shares are trading higher today, continuing a trend since Thursday's close, despite notable volatility during the session.

5 aug 2026, 19:36 UTC

AnaptysBio Inc. shares are lower in Wednesday's session, having declined from earlier highs amid routine market fluctuations and trading near the lower end of its recent range.

3 aug 2026, 20:06 UTC

AnaptysBio Inc shares are higher today, recovering from earlier losses amid a broader market rally in the S&P 500 and Nasdaq 100 indices.

31 jul 2026, 20:06 UTC

AnaptysBio Inc shares are lower, reflecting broader market weakness amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 jul 2026, 23:36 UTC

AnaptysBio Inc. shares declined after-market, reflecting ongoing weakness amid broader market volatility and the Federal Reserve's interest rate decisions.

29 jul 2026, 19:56 UTC

Macro Event

AnaptysBio Inc shares are higher, recovering from an earlier dip, amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

28 jul 2026, 23:16 UTC

AnaptysBio Inc shares are higher in after-market trading, recovering from earlier lows. No specific news was identified to explain the movement.

24 jul 2026, 19:16 UTC

AnaptysBio Inc shares are lower today, reflecting a decline since Thursday. Broader market sentiment is affected by recent volatility in oil prices.

23 jul 2026, 09:16 UTC

AnaptysBio Inc is trading lower in pre-market hours amid broader market pressures from disappointing earnings reports and rising geopolitical tensions.

22 jul 2026, 22:16 UTC

AnaptysBio Inc shares are higher in after-market hours, trading above Wednesday's close amid broader market concerns over rising crude oil prices and U.S.-Iran tensions.

21 jul 2026, 20:12 UTC

AnaptysBio Inc. shares are lower in after-market trading, continuing a downward trend and positioning the stock below its 20-day moving average.

20 jul 2026, 23:01 UTC

AnaptysBio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Peer Vergelijking

Prijswijziging

AnaptysBio Inc Prognose

Koersdoel

By TipRanks

42.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 80.67 USD 42.5%

Hoogste 95 USD

Laagste 70 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor AnaptysBio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan AnaptysBio Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

151 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.